KR20230069984A - Tyk2 억제제 및 그의 용도 - Google Patents
Tyk2 억제제 및 그의 용도 Download PDFInfo
- Publication number
- KR20230069984A KR20230069984A KR1020237012767A KR20237012767A KR20230069984A KR 20230069984 A KR20230069984 A KR 20230069984A KR 1020237012767 A KR1020237012767 A KR 1020237012767A KR 20237012767 A KR20237012767 A KR 20237012767A KR 20230069984 A KR20230069984 A KR 20230069984A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- solvate
- stereoisomer
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079217P | 2020-09-16 | 2020-09-16 | |
| US63/079,217 | 2020-09-16 | ||
| PCT/US2021/050649 WO2022060973A1 (en) | 2020-09-16 | 2021-09-16 | Tyk2 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230069984A true KR20230069984A (ko) | 2023-05-19 |
Family
ID=78086111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237012767A Pending KR20230069984A (ko) | 2020-09-16 | 2021-09-16 | Tyk2 억제제 및 그의 용도 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230357273A1 (https=) |
| EP (1) | EP4214215A1 (https=) |
| JP (1) | JP7824938B2 (https=) |
| KR (1) | KR20230069984A (https=) |
| CN (1) | CN117279922B (https=) |
| AU (1) | AU2021345181A1 (https=) |
| CA (1) | CA3192621A1 (https=) |
| IL (1) | IL301385A (https=) |
| WO (1) | WO2022060973A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| JP2025509596A (ja) * | 2022-03-16 | 2025-04-11 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| WO2023178235A1 (en) * | 2022-03-16 | 2023-09-21 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
| WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
| WO2024199479A1 (zh) | 2023-03-31 | 2024-10-03 | 北京普祺医药科技股份有限公司 | 一种大环化合物、药物组合物及其用途 |
| WO2024222807A1 (en) * | 2023-04-27 | 2024-10-31 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Novel macrocyclic heteroaryl derivatives as kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2864839T3 (es) * | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| ES2902995T3 (es) * | 2016-10-07 | 2022-03-30 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| TWI808958B (zh) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| CN120865208A (zh) * | 2019-01-23 | 2025-10-31 | 武田药品工业株式会社 | Tyk2抑制剂和其用途 |
| US20220135567A1 (en) * | 2019-02-07 | 2022-05-05 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| CA3132632A1 (en) * | 2019-03-11 | 2020-09-17 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| AU2020247990A1 (en) * | 2019-03-26 | 2021-11-11 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
-
2021
- 2021-09-16 AU AU2021345181A patent/AU2021345181A1/en active Pending
- 2021-09-16 JP JP2023517268A patent/JP7824938B2/ja active Active
- 2021-09-16 IL IL301385A patent/IL301385A/en unknown
- 2021-09-16 WO PCT/US2021/050649 patent/WO2022060973A1/en not_active Ceased
- 2021-09-16 US US18/026,309 patent/US20230357273A1/en active Pending
- 2021-09-16 CA CA3192621A patent/CA3192621A1/en active Pending
- 2021-09-16 KR KR1020237012767A patent/KR20230069984A/ko active Pending
- 2021-09-16 EP EP21789976.4A patent/EP4214215A1/en active Pending
- 2021-09-16 CN CN202180076687.5A patent/CN117279922B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021345181A9 (en) | 2024-06-20 |
| WO2022060973A1 (en) | 2022-03-24 |
| CA3192621A1 (en) | 2022-03-24 |
| AU2021345181A1 (en) | 2023-05-04 |
| IL301385A (en) | 2023-05-01 |
| JP2023541203A (ja) | 2023-09-28 |
| CN117279922A (zh) | 2023-12-22 |
| US20230357273A1 (en) | 2023-11-09 |
| EP4214215A1 (en) | 2023-07-26 |
| JP7824938B2 (ja) | 2026-03-05 |
| CN117279922B (zh) | 2025-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12351572B2 (en) | Substituted 1,2,4-triazoles as TYK2 inhibitors | |
| JP7824938B2 (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| KR102899985B1 (ko) | Tyk2 억제제 및 그의 용도 | |
| KR20240162539A (ko) | Tyk2 억제제 및 그의 용도 | |
| JP2025509594A (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| HK40105557B (zh) | Tyk2抑制剂及其用途 | |
| HK40105557A (zh) | Tyk2抑制剂及其用途 | |
| HK40119624A (en) | Tyk2 inhibitors and uses thereof | |
| HK40120037A (en) | Tyk2 inhibitors and uses thereof | |
| HK40120037B (en) | Tyk2 inhibitors and uses thereof | |
| HK40119624B (en) | Tyk2 inhibitors and uses thereof | |
| HK40065275A (zh) | Tyk2抑制剂和其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |